Gastro Medical News about Colitis, Ulcerative

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
CMS Revises Consignment Closet Provisions

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis
Inflammatory Bowel Disease, 11/04/09

Lukas M et al. – In the uncontrolled trial, administration of exogenous AP enzyme daily over a 7–day course to patients with UC was associated with short–term improvement in disease activity scores, with clinical effects being observed within 21 days and associated with reductions in C–reactive protein and stool calprotectin. AP enzyme treatment was well tolerated and nonimmunogenic.

<< Previous
Prognosis of adult patients transplanted with liver grafts < 35%...

Next >>
Pyogenic Liver Abscess Spontaneously Drained Into the Stomach